Document Detail


A collection method and high-sensitivity enzyme immunoassay for sweat pyridinoline and deoxypyridinoline cross-links.
MedLine Citation:
PMID:  10471653     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Collagen cross-link molecules such as pyridinoline (PYD), deoxypyridinoline (DPD), and N-terminal cross-linked peptides (NTX) have been measured in urine as indices of bone resorption. However, very little is known regarding the excretion of pyridinolines into other biological fluids. We report a collection device, normalizing analyte, and high-sensitivity immunoassay for quantitative analysis of free pyridinoline cross-links in sweat. METHODS: Flame atomic emission and ion-selective electrode techniques were used to measure potassium as a sweat volume marker. The Pyrilinks immunoassay for urine free pyridinolines was optimized to increase sensitivity for measurements in sweat. The precision, accuracy, and detection limit of this assay were characterized. To assess values and variability of sweat pyridinolines in human subjects, a nonocclusive skin patch was used to collect sweat samples from a reference group and from a mixed group experiencing accelerated bone resorption, postmenopausal women and men receiving gonadotropin-releasing hormone for prostate cancer. RESULTS: The immunoassay intra- and interassay variations were </=10% and <16%, respectively, with a detection limit of 309 pmol/L. Linearity upon dilution and analytical recovery ranged from 93% to 109% and 85% to 122%, respectively. Sweat PYD values normalized to potassium output yielded a weekly intraindividual biological variability of 14.7%. The mean increase in the population experiencing increased bone resorption vs the reference group was 36% (P <0.05) for sweat PYD/K vs 23-40% (P <0.05) for urinary PYD/Cr, DPD/Cr, and NTX/Cr. CONCLUSION: We conclude that this new platform sweat collection technology and PYD immunoassay show potential as an indicator of bone resorption.
Authors:
M Sarno; H Powell; G Tjersland; D Schoendorfer; H Harris; K Adams; P Ogata; G R Warnick
Related Documents :
18757953 - The exercise-related rise in plasma cobalt levels after metal-on-metal hip resurfacing ...
2333783 - Exercise patterns and trabecular bone density in college women.
468633 - Effect of hyperoxia on oxygen consumption in exercising ponies.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical chemistry     Volume:  45     ISSN:  0009-9147     ISO Abbreviation:  Clin. Chem.     Publication Date:  1999 Sep 
Date Detail:
Created Date:  1999-09-15     Completed Date:  1999-09-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9421549     Medline TA:  Clin Chem     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1501-9     Citation Subset:  IM    
Affiliation:
Vision Biotechnology Consulting, 306-N W El Norte Pkwy., PMB 311, Escondido, CA 92026, USA. mjsarno@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amino Acids / analysis*
Antineoplastic Agents, Hormonal / therapeutic use
Biological Markers / analysis
Bone Resorption / metabolism,  urine
Collagen / analysis*,  chemistry
Cross-Linking Reagents / analysis*
Female
Humans
Immunoenzyme Techniques
Leuprolide / therapeutic use
Male
Postmenopause / metabolism
Potassium / analysis
Prostatic Neoplasms / drug therapy,  metabolism,  urine
Reference Values
Spectrophotometry, Atomic
Sweat / chemistry*
Chemical
Reg. No./Substance:
0/Amino Acids; 0/Antineoplastic Agents, Hormonal; 0/Biological Markers; 0/Cross-Linking Reagents; 53714-56-0/Leuprolide; 63800-01-1/pyridinoline; 7440-09-7/Potassium; 90032-33-0/deoxypyridinoline; 9007-34-5/Collagen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Predictive value of cord blood hematological indices and hemoglobin Barts for the detection of heter...
Next Document:  Total and free deoxypyridinoline after acute osteoclast activity inhibition.